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Abstract 
Aims and objectives.  To evaluate the effect of a stop smoking clinic on the quit rates of patients admitted to an 
acute in-patient unit. 
Background.  The relationship between poor physical health and severe mental illness is well established. High 
rates of smoking appear to play an important causal role in the excess morbidity and mortality in this population. 
Stop smoking interventions for the general population are clinically effective and cost-effective. There is a small 
but promising evidence base for effective interventions to help people with a mental illness who wish to stop 
smoking but these have mostly been tested with community patients rather than acute in-patients. 
Methods.  A service evaluation of a drop-in stop smoking clinic on an acute mental health in-patient unit was 
conducted. Patients’ smoking status was measured at baseline and four weeks after their quit date using patient 
self-report and an expired breath carbon monoxide reading. 
Results.  Over a six-month evaluation period, 46 patients set a quit date and 13 (28·3%) were abstinent at the 
four-week follow-up stage, verified by a carbon monoxide reading (χ2 = 33, df = 1, P  < 0·0001). 
Conclusions. This small-scale evaluation has shown a drop-in stop smoking intervention to be feasible, 
acceptable and associated with positive outcomes; further research with larger, more representative samples is 
required. 
Relevance to clinical practice. Enforcing smoke-free legislation is a contentious issue on mental health in-
patient units, and there is a paucity of research to guide nursing practice in this area. An admission period in a 
smoke-free environment provides a crucial opportunity to offer smoking cessation treatment. With appropriate 
resources, expertise and support, it appears possible to apply smoking cessation interventions that are successful  
 
Introduction 
The relationship between poor physical health and severe mental illness (SMI) such as schizophrenia and 
bipolar disorder is well established. People with SMI frequently have coexisting long-term medical conditions, 
such as chronic respiratory disease, cardiovascular disease and type 2 diabetes (Osborn et al. 2007, 2008), and it 
has been estimated that the life expectancy of people with SMI is reduced by 10–25 years (Newman & Bland 
1991, Parks et al. 2006, Chang et al. 2011). High rates of smoking appear to play an important causal role in the 
excess morbidity and mortality in people with SMI (Brown et al. 2000). The risk of many diseases, in particular 
respiratory, cardiovascular disease and some cancers in people with SMI could therefore be reduced by 
providing appropriate smoking cessation support (Campion et al. 2008). 
 
Background 
Despite a steady reduction in the prevalence of smoking over the past 50 years in the United Kingdom (UK) and 
other industrialised nations, tobacco use remains the single greatest cause of preventable illness and premature 
death in the world (WHO 2009). Approximately 21% of the UK population are current smokers (Health and 
Social Care Information Centre, 2010), which is similar to the current rates in the USA and Australia (Centres 
for Disease Control and Prevention 2009, McCarthy et al. 2010). The prevalence of daily smoking for patients 
with major depression, bipolar disorder and schizophrenia is estimated to be 57, 66 and 74%, respectively (Diaz 
et al. 2009). The highest levels of smoking occur within psychiatric in-patient settings. In a meta-analysis of 42 
studies investigating the prevalence of smoking in people with schizophrenia, 68% of in-patients were smokers 
compared to 57% of community patients (de Leon & Diaz 2005). People with SMI are likely to be heavier 
smokers (Kumari & Postma 2005) and those who smoke are more likely to experience more severe psychotic 
symptoms and have poorer outcomes compared to non-smokers (Aguila et al. 2005). National epidemiological 
survey findings indicate that approximately 43% of cigarette smoking is by people with a mental illness (Lasser 
et al. 2000, McManus et al. 2010). Unlike in the general population, smoking prevalence is not declining in the 
SMI population, exposing people with SMI who smoke to additional health inequalities and social exclusion. 
 
Reducing rates of smoking in the general population has been a longstanding public health goal, and there is 
consistent evidence that providing dedicated services to help smokers quit is both clinically effective and cost-
effective (Raw et al. 2005). Primary Care Trusts (PCTs) in England are responsible for providing smoking 
cessation services for people who want to quit. Standard National Health Service (NHS) care includes 
approximately 6 sessions of behavioural support and pharmacotherapy based on a withdrawal orientated model 
and emphasises the importance of complete abstinence (West et al. 2000, McEwen et al. 2006a). The choices of 
medication available to people attending NHS stop smoking services who are motivated to stop smoking are 
usually based on patient preference and include nicotine replacement therapy (NRT), Bupropion and 
Varenicline. The effectiveness of pharmacotherapy and/or behavioural support for people in the general 
population to stop smoking has been evaluated in over 200 randomised controlled trials (RCTs) including over 
70,000 patients and has been shown to increase the chance of quitting 2- to 4-fold, compared to placebo 
(Hughes et al. 2007, Stead et al. 2008, Cahill et al. 2012). NRT aims to reduce withdrawal symptoms associated 
with stopping smoking by replacing the nicotine from cigarettes; it is widely used and has few side effects. 
Bupropion is an antidepressant and a nicotine antagonist. Recent systematic reviews have found it to be 
effective in helping people with schizophrenia to stop smoking (Banham & Gilbody 2010, Tsoi et al. 2010), but 
is also known to lower the seizure threshold, induce mania and interacts with a number of psychotropic 
medications (NICE 2008). Varenicline is a nicotine acetylcholine receptor partial agonist. Case reports indicate 
significant risks of exacerbation of depression, bipolar disorder and suicidal ideation whilst taking Varenicline 
and have led the Medicines and Healthcare Products Regulatory Agency (2008) to recommend that Varenicline 
should be used with care with patients who have a history of psychiatric illness. 
 
The National Institute for Health and Clinical Excellence (NICE) recommends that NHS Stop Smoking Services 
in the UK should aim to treat a minimum of 5% of their local population of smokers in the course of a year and 
at least 35% of treated smokers who set a quit date should be abstinent four weeks after their quit date (National 
Institute for Health and Clinical Excellence 2008). Four-week quit smoking rates are a mandatory monitoring 
requirement for English NHS Stop Smoking Services and a means of tracking service performance (Department 
of Health 2009). These data are collected on a quarterly basis by patient self-report, validated by an expired 
breath carbon monoxide (CO) reading of <10 ppm. From April 2009 to March 2010, 757,537 people set a quit 
date with NHS Stop Smoking Services in England and 49% had successfully stopped smoking at the four-week 
follow-up stage (The Health and Social Care Information Centre 2010). 
 
In 2006, smoke-free legislation was introduced to ban smoking in enclosed public areas or workplaces in 
England (Health Act, 2006). Following an initial exemption, mental health units in England and Northern 
Ireland have had to comply with smoke-free legislation since July 2008. Implementation has been contentious 
and surveys since the ban suggest that it is only being partially implemented, and that mental health staff and 
patients remain ambivalent about its utility and feasibility (Mental Health Foundation 2009). 
 
Retrospective service evaluations of the impact of the smoking ban in in-patient forensic settings in the UK have 
been carried out (Cormac et al. 2010, Shetty et al. 2010), but these do not report quit rates. An emerging 
evidence base suggests that when smoking cessation interventions are tailored to address the neurobiological, 
cognitive, affective and social effects of SMI, a modest number of patients are motivated and successful in 
stopping smoking. Uncontrolled and controlled studies evaluating the efficacy of NRT or Bupropion, in addition 
to psychosocial support, report quit rates of between 6–18% at six-month follow-up amongst community 
patients with psychosis (George et al. 2000, 2002, 2008, Evins et al. 2001, 2005, 2007, Baker et al. 2006, 
Ashton et al. 2010). However, amongst UK acute in-patients with SMI, we were unable to identify any 
published studies prospectively evaluating a smoking cessation intervention. 
 
The Department of Health (DH) in the UK recommends that commissioners and providers should work together 
to improve access to evidence-based smoking cessation treatment for smokers from high-risk groups such as 
people with mental illness. The DH also proposes that new, non-evidence-based delivery models (such as drop-
ins) should be piloted on a small scale and be carefully evaluated before being adopted as a significant part of 
the service (DH 2009). 
 
This article reports the results of a prospective service evaluation of a drop-in stop smoking clinic jointly 
developed by a PCT and a Mental Health Trust in the UK, designed to help patients on an acute mental health 
in-patient unit to stop smoking. The aim of the study was to evaluate the effect of the drop-in stop smoking 
clinic on the smoking status of patients four weeks after their quit day. 
 
Method 
Setting and participants 
The service evaluation took place on an acute in-patient unit of a NHS Mental Health Foundation Trust in the 
south of England between July 2008 and March 2009. This unit was comprised of two 18-bedded acute 
admission wards and a seven-bedded Psychiatric Intensive Care Unit, which serves a population of 
approximately 395,000 people from four districts (NHS Surrey 2008). White British ethnicity makes up the 
largest percentage of the resident population (84·4%), compared to the national average of 83·6% for the whole 
of England, whereas people from an Asian background are the largest minority non-white group in this area 
(NHS Surrey 2008). The PCT where the research was conducted is the least deprived PCT and the third most 
affluent county in England (NHS Surrey 2008). However, there are pockets of relative deprivation and the in-
patient site reported in this study admits patients from two of the most deprived districts in the county. All 
patients aged 18 and above who were resident on the in-patient unit and who smoked during the evaluation 
period were eligible to access the drop-in clinic on a voluntary basis, either by self-referring or by referral from 
a member of staff. 
 
Description of the service 
A steering group was established to oversee the development, management and evaluation of the drop-in clinic. 
Members included the PCT tobacco control lead for mental health, two Trust managers, a ward manager, a staff 
nurse, a pharmacist and an honorary nurse consultant. The drop-in clinic was held one day a week for six hours, 
over a six-month period. The first three months of the drop-in clinic were staffed by a specialist stop smoking 
advisor employed on a freelance basis by the PCT. She had 10 years’ experience working in the field of 
smoking cessation and a background in mental health nursing and social work. The rationale for using an 
experienced specialist stop smoking advisor employed by the PCT to set-up the clinic was to try and have a 
positive impact on the culture and practice of the unit staff. We wanted a confident practitioner who had a 
proven track record of success in helping patients with SMI to stop smoking and who would hopefully inspire 
patients to use the service and demonstrate to the unit staff that this was a worthwhile and achievable task. The 
steering group also considered it important that the stop smoking advisor should be external to the in-patient unit 
to prevent conflict with competing ward priorities and untoward incidents. 
 
After the initial three months, the drop-in clinic was staffed by three mental health in-patient workers, a staff 
nurse, an occupational therapy technician and a health care assistant, who worked in turn to staff the drop-in 
clinic on a rota basis. Their time working in the drop-in clinic was ring-fenced and funded by the Mental Health 
Trust. Prior to taking over the running of the drop-in clinic (i.e. during the first three months of the clinic), these 
three mental health workers attended a Level 2 smoking cessation training course for mental health 
professionals, run by the local PCT. They received 14 hours of training delivered over two and a half 
consecutive days by tobacco control specialists. The course is designed to provide mental health professionals 
with knowledge, confidence and skills to deliver smoking cessation advice on a one-to-one basis and is 
compliant with the standards for training in smoking cessation treatments recommended by the Health 
Development Agency (HDA 2003) in the UK. 
 
Staff running the drop-in aimed to deliver 6–8 sessions of smoking cessation support based on the work 
developed and described by Hajek (1989) and McEwen et al. (2006a) for use in the general population and by 
McNally (2006) for mental health patients. It was decided by the steering group that because of the potential 
interactions of Bupropion with some psychotropic medication and the lack of current empirical evidence and 
potential risks of Varenicline in a mental health population, patients would only be offered NRT (patch, 
inhalator or lozenge). In addition to NRT, other interventions used in the drop-in included engaging patients in 
setting a flexible and collaborative quit date; monitoring nicotine withdrawal symptoms, coping with physical, 
psychological, social and behavioural aspects of stopping smoking and relapse prevention. If a patient was 
discharged before the intervention was completed, they had the option of returning to the unit or being followed 
up by the PCT stop smoking service. 
 
Outcomes 
Smoking status 
The primary outcome for the study was smoking status four weeks after the patient’s quit day. This was 
obtained by patient self-report and validated by an expired carbon monoxide (CO) reading taken each week by 
the drop-in staff, over this four-week period. Expired breath CO reading is the most commonly used biological 
marker of smoking status in both research studies and clinical practice (Jarvors et al. 2005). CO is a colourless, 
odourless gas inhaled by smokers from cigarettes. CO is eliminated from the body within 24 hours of stopping 
smoking; therefore, if a patient reports they have not smoked in the previous 24 hours, an exhaled breath test can 
confirm this (American Lung Association 1990). The proportion of CO-verified patients was calculated by 
dividing the number of treated smokers who reported continuous abstinence from smoking from quit day to the 
four-week follow-up point and who had a CO reading of <10 ppm, by the total of treated smokers (DH 2009). 
 Clinical and smoking characteristics 
Demographic and clinical characteristics were collected from case notes, and smoking characteristics were 
collected at baseline by the drop-in staff using the Smoker’s Clinic Questionnaire, a data collection tool used 
routinely by the local PCT NHS Stop Smoking Service. This tool was used at the first smoking cessation session 
to assess the patients’ level of nicotine dependence and their motivation to smoke and stop smoking. The 
Fagerstrom Test for Nicotine Dependence (FTND) is the most widely used instrument to quantify dependence 
(Heatherton et al. 1991) and been used to assess dependency in studies of smoking cessation interventions in 
mentally ill samples (George et al. 2000, Evins et al. 2005, 2007, Baker et al. 2006). Two of the items in the 
FTND (the number of cigarettes smoked and time to first cigarette of the day) are included in the Smoker’s 
Clinic Questionnaire. These two questions have been identified to be valid and the most predictive values of 
nicotine dependence and can be combined to give a Heaviness of Smoking Index (HSI) score (Heatherton et al. 
1989, John et al. 2004). In mental health samples, the scores derived from the HSI and FTND have high 
agreement (kappa 0·60) (de Leon et al. 2003). Using the HSI, dependence can be categorised into one of three 
groups: low (0–1), medium (2–4) and high dependence (5–6). 
 
Reasons for smoking are also elicited in the Smoker’s Clinic Questionnaire, using some of the questions from 
The Smoking Motives Questionnaire (SMQ) (West 2006). Patients are asked to rate how often they use smoking 
to help cope with stress, to socialise, to help with concentration, because they will feel uncomfortable if they do 
not smoke, to keep weight down and because they enjoy it (1 = not at all and 5 = very much). The SMQ is used 
in the Smoking Toolkit study (West 2006), a series of monthly surveys designed to provide information on 
smoking and cessation patterns amongst smokers in England. Its test–retest reliability has been found to be 
generally high (McEwen et al. 2008) and smoking motives elicited using the questionnaire have been found to 
be correlated with a number of sociodemographic variables (Fidler & West 2009). 
 
The types of data used in this study are routinely collected by the local PCT Stop Smoking Service and the 
Mental Health Trust. Data were collated and analysed by a member of the steering group who was independent 
to the drop-in clinic staff. Ethical approval for service evaluations is not required (McEwen et al. 2006b, NHS 
National Patient Safety Agency 2008), although audit approval was obtained from the Mental Health Trust’s 
Research & Development department. 
 
Analysis 
Data were entered and analysed using spss version 15 (SPSS, Chicago, IL, USA) and stata version 9 (Stata 
Corporation, College Station, TX, USA). Demographic, clinical and smoking characteristics are described using 
means and standard deviations for continuous variables and percentages for categorical variables. The McNemar 
test (a paired version of the chi-square test) was used to test if the number of patients who stopped smoking was 
significantly different between baseline and the four-week follow-up stage (McNemar 1947). 
 
Results 
During the six-month evaluation period, 46 in-patients used the drop-in clinic and set a quit date. The 
demographic and clinical characteristics are reported in Table 1. 
 
Table 1: Demographic and clinical characteristics 
Variable N = 46 
Gender 
Female 28 (61%) 
Age 36·6 (SD 12·8) 
Ethnicity 
White UK 37 (80·4%) 
Diagnosis 
Schizophrenia 18 (39·1%) 
Personality disorder 11 (23·9%) 
Depression 10 (21·9%) 
Bipolar 7 (15·2%) 
Legal status detained under Mental Health Act 20 (43·4%) 
Mean length of admission 63 days 
 
 
Smoking characteristics 
Participants smoked an average of 28 (SD 15·4) cigarettes a day (range, 4–80) and their HSI score was 3·8 (SD 
1·47). Sixty-three per cent had previously tried to stop smoking on at least one occasion, and the mean length of 
time for previous abstinence was 48·7 days (SD 83·1). The highest rated motive for smoking was to help cope 
with stress (mean, 4·2, SD 1·2): 79% of patients stated they did this ‘very much’ or ‘quite a bit’. The next 
highest rated motive reported was the enjoyment of smoking (mean, 4·1, SD 1·2), followed by to help with 
socialising (mean, 3·3, SD 1·4), and because they would feel uncomfortable if they did not smoke (mean, 3, SD 
1·5). Thirty-eight per cent of participants stated they were either very or extremely determined to stop smoking, 
and 34·4% thought it was very or extremely important to stop smoking. The most common reason given for 
wanting to stop smoking was for health reasons: 70·4% gave this reason, followed by cost (11·1%), pressure 
from others (11·1%), not liking being addicted (3·7%) and that it was a bad example to their children (3·7%). 
 
Smoking status 
Over the six-month evaluation period, 46 patients were treated in the drop-in clinic and set a quit date. Thirteen 
(28·3%) patients were abstinent at the four-week follow-up stage, verified by a CO reading (χ2 = 33, df = 1,  
P < 0·0001); this was a statistically significant proportion of those treated. Five of the ten patients with a 
diagnosis of depression successfully quit, whereas 5 of 18 patients with a diagnosis of schizophrenia, 2 of 11 
patients with a personality disorder and one of seven patients with a bipolar disorder successfully stopped 
smoking. 
 
The specialist smoking cessation advisor employed by the PCT treated 27 patients in the first three months of 
the drop-in and 10 (37%) patients quit at four-week follow-up. The ward staff, new to smoking cessation work, 
treated 19 patients in the second three months of the evaluation and 3 (15·7%) patients quit. This difference was 
not statistically significant (χ2 = 2·48, df = 1, P =  0·11). 
 
Discussion 
This study is to our knowledge the first published UK evaluation of a smoking cessation intervention, 
exclusively for an acute mental health in-patient population. This evaluation shows that these patients are 
motivated to stop smoking and that a significant proportion find this achievable. The participants in this 
evaluation were heavy smokers [defined as smoking more than 25 cigarettes a day (Kelly & McCreadie 1999)] 
and had a moderate level of tobacco dependence. They were motivated to smoke for reasons similar to those of 
smokers in the general population: data collected from more than 2700 clients of London Stop Smoking 
Services rated stress relief, boredom and enjoyment highest (McEwen et al. 2008). The average length of stay 
on the in-patient unit for our participants was similar to the UK national average length of an in-patient stay, 
currently reported as 78 days for men and 68 for women, as was the proportion of those who were compulsorily 
detained (Health and Social Care Information Centre 2011). 
 
An in-patient stay in a smoke-free environment may be an opportune time for initiating smoking cessation 
treatment because of the intensity of exposure to nursing and medical staff and the removal from usual 
environmental cues to smoke (American Psychiatric Association 2006). Rigotti et al. (2008) reported that 
delivering smoking cessation services to in-patients with physical health conditions, such as cardiovascular 
disease has a positive impact. Pooling data from 17 RCTs, they found that cessation programmes initiated 
during a hospital stay, and which included follow-up support for at least one month after discharge, increased 
the odds of stopping smoking by 65% at 6–12 months after hospital discharge. Published studies of similar 
programmes in people with SMI do not currently exist. 
 
Despite recommendations to integrate smoking cessation interventions into mental health services (Campion et 
al. 2008, DH 2009), there is lack of clarity about the role that in-patient staff should adopt. The current evidence 
base for effective interventions to help people with a SMI who wish to stop smoking is derived from community 
patients rather than acute in-patients. Also, the majority of studies to assess the efficacy of smoking cessation 
interventions have been conducted in research settings where the intervention is usually delivered by a research 
nurse or trained smoking cessation counsellor, not by a heath care professional responsible for other aspects of 
the patients’ clinical care (Rigotti et al. 2008). It has been established that nurses who combine smoking 
cessation work with other duties are less effective than nurses who have a health promotion or an exclusive 
smoking cessation role (Rice & Stead 2008). Our drop-in clinic was a dedicated on-site service, staffed initially 
by a specialist smoking cessation advisor and then by ward staff following brief training. The specialist stop 
smoking advisor treated more patients and achieved higher quit rates than the ward staff; however, it is 
uncertain if this was as a result of greater experience and specialist skills or her exclusive role in concentrating 
on smoking behaviour. Nevertheless, the in-patient staff were able to motivate patients to make a quit attempt 
and this was successful for a small number, suggesting that in-patient mental health staff whose role is varied 
and challenging are able to integrate smoking cessation work into their clinical practice when their time is 
protected. 
 
Lawn and Campion (2010) surveyed 99 adult mental health in-patient units across Australia to evaluate the 
implementation of smoke-free legislation. They reported that the factors associated with greater success of 
implementing smoke-free initiatives in mental health in-patient settings are clear, consistent and visible 
leadership, cohesive teamwork, extensive training for clinical staff, fewer staff smokers, effective use of 
nicotine replacement therapies and consistent enforcement of a smoke-free policy. In the current study, it 
appeared that the consistent and visible leadership from the ward manager, the cohesive teamwork of the three 
mental health workers who ran the drop-in and the collaborative support from the local PCT were integral to the 
success of the drop-in service. 
Current guidelines recommend that general population services should aim to achieve a CO-validated abstinence 
rate of at least 35% four weeks after the person stops smoking (National Institute for Health and Clinical 
Excellence 2008). The local PCT NHS Stop Smoking Service responsible for providing support to smokers in 
the general population achieved a quit rate of 41% during the same time period as our service evaluation (Health 
and Social Care Information Centre 2009). The rate of 28% achieved in this service is clearly lower than these 
general population targets and results. But although mental health services should aim for comparable quit rates 
between mental health service users who smoke and smokers in the general population, there is a paucity of 
evidence to guide our practice about what is an achievable and realistic target. It is likely that smokers who have 
mental illness will have more severe nicotine dependence and greater ambivalence about stopping compared to 
smokers in the general population (Tsoi et al. 2010), which may be expected to limit the effectiveness of 
standard care interventions. 
 
The findings of this study need to be cautiously interpreted because of its methodological limitations: this was 
uncontrolled study and hence vulnerable to subjectivity and bias. The sample size was small and recruited from 
a single site; therefore, it may not be representative or generalisable to similar populations. The Mental Health 
Trust where the study was conducted did not routinely record patient’s smoking status at the time, so we are 
unable to report what proportion of the in-patients were smokers and therefore what proportion of smokers were 
interested in making a quit attempt during their stay. We also did not collect any routine data regarding the 
severity of symptoms of this sample of patients and how this may have affected their desire to use the drop-in 
clinic or influenced their ability to quit. Follow-up data were only collected for four weeks after the patients quit 
date, in line with national monitoring standards; therefore, we do not know whether these quit attempts were 
sustained beyond this time period. However, this study has generated new knowledge at a local level and was 
conducted in a real world as opposed to a research setting. The most robust design for the evaluation of a new 
intervention or service is a well conducted randomised controlled trial; however, a series of studies may be 
required to progressively refine an intervention before one embarks on a full-scale evaluation (Craig et al. 
2008). Compared to the large, robust evidence base for smoking cessation interventions for smokers in the 
general population, interventions to help people with SMI have a smaller evidence base, and to date published 
studies have focused on patients in community mental health settings. Clinical interventions evaluated in the 
general population provide an essential starting point on which to build approaches specific to the needs of this 
particular population. The challenge of taking evidence-based interventions that are effective in smokers in the 
general population and adapting them for mental health patients who smoke is an important public health 
priority and the basis of this study. 
 
Conclusion 
This service evaluation of a stop smoking drop-in clinic highlights that patients in an acute in-patient unit are 
interested in stopping smoking and that a significant proportion find this achievable. Enforcing smoke-free 
legislation has become a time-consuming and contentious issue on in-patient units, particularly in the UK. 
However, an admission period in a smoke-free environment provides a crucial opportunity to offer smoking 
cessation treatment, although this will only be viable with appropriate resources expertise and support. This 
small-scale evaluation has shown a drop-in intervention to be feasible, acceptable and associated with positive 
outcomes; further research with larger, more representative samples to guide our practice is required. 
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